Quick Takeaways
- Royalty Pharma Sub-Manager, LLC reports institutional holdings through Form 13F filings.
- Latest reported quarter: Q4 2025.
- Latest reported holdings value: $125,447,273.
- Info
- Portfolio
13F Filings History of Royalty Pharma Sub-Manager, LLC
- Latest 13F report
- Q4 2025 - 01 Apr 2026
- Value $
- $125,447,273
- Signature - Title
- Jason Mehar - SVP, Investments & Deputy General Counsel
- Location
- New York, NY
- Summary
- This page shows a list of all the recent 13F filings made by Royalty Pharma Sub-Manager, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Royalty Pharma Sub-Manager, LLC reported 4 stock holdings with total value $125,447,273 as of Q4 2025. Top holdings included CYTK, BHVN, and BCRX.
Follow Filing Activity
Follow Royalty Pharma Sub-Manager, LLC and return when a new 13F portfolio filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Holdings Value
What Changed
- Most recent filing was accepted on 01 Apr 2026, 16:40.
- Historical comparison will expand as more 13F quarters are available.
Why This Matters
- This gives a plain-language read of holdings direction before you open full quarter tables.
- Use the filing links below to verify the exact SEC source document.
Official SEC Source
Backed by Form 13F
Portfolio holdings and changes are grounded in SEC Form 13F filings.
See Original Filing| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 4 | $125,447,273 | $0 | $0 | $0 | CYTK, BHVN, BCRX | 13F-HR | 01 Apr 2026, 16:40 |